News


Following a collaboration between Polytheragene, Genethon and Yposkesi (an industrial platform created by the AFM-Telethon in Genopole), the PTG1-plus polymer of the PTG1 family has shown a remarkable transfection efficiency of cells producing viral vectors (AAV and Lentivirus) with remarkably low toxicity.

See the article in Genopole newsletter of April:

https://www.genopole.fr/Vers-l-industrialisation-en-therapie-genique.html?utm_source=newsletter&utm_medium=email&utm_campaign=nl99#.XqMQVHvgrIU

A protocol has been developed for the bioproduction of these viral vectors on an industrial scale in bioreactors of 200 to 400 liters. The production of viruses with PTG1-plus was much more effective than that obtained with competing transfection reagents, particularly with respect to the high level of complete viral particles.This scaling up is an essential lever to hope to reduce the costs of production and achieve more reasonable drug prices.

The results were presented at the annual conference of the European Society of Genetic and Cell Therapy (ESGCT) held in Barcelona from 22 to 25 October 2019. Poster P063 and P082

Following these results, Genethon has entered into a license agreement for the use of PTG1 plus. Yposkesi, the leader in Europe for the large-scale production of viral vectors for gene therapy, has also concluded a contract to supply PTG1 plus.